Berghagen Hege, Ragnhildstveit Erlend, Krogsrud Kristin, Thuestad Gunnar, Apriletti James, Saatcioglu Fahri
Biotechnology Centre of Oslo, University of Oslo, Postboks 1050 Blindern, Oslo 0316, Norway.
J Biol Chem. 2002 Dec 20;277(51):49517-22. doi: 10.1074/jbc.M209546200. Epub 2002 Oct 17.
Nuclear receptors are ligand-modulated transcription factors that transduce the presence of lipophilic ligands into changes in gene expression. Nuclear receptor activity is regulated by ligand-induced interactions with coactivator or corepressor molecules. From a positive hormone response element (pHRE) and in the absence of hormone, corepressors SMRT and N-CoR are bound to some nuclear receptors such as the thyroid hormone (T3Rs) and retinoic acid receptors and mediate inhibition of basal levels of transcription. Ligand binding results in dissociation of corepressors and association of coactivators, resulting in the reversal of inhibition and a net activation of transcription. However, the role of cofactors on the activity of nuclear receptors from negative HREs (nHREs) is poorly understood. Here we show that corepressor SMRT can act as a potent coactivator for T3Ralpha from a nHRE; N-CoR has a similar but significantly attenuated activity. Mutagenesis of residues in the hinge region of T3Ralpha that block binding of SMRT and N-CoR inhibits ligand-independent transcriptional activation by T3Ralpha from a nHRE. These mutations also abrogate SMRT-mediated increase in transcriptional activity by T3Ralpha at a nHRE without significantly affecting ligand-dependent activation at a pHRE. Partial protease digestion coupled to the mobility shift assay indicate differences in the conformation of T3Ralpha-SMRT complexes bound to a pHRE versus a nHRE. These results suggest that allosteric changes resulting from binding of T3Ralpha to different response elements, i.e. pHREs versus nHREs, dictate whether a cofactor will function as a coactivator or a corepressor. This, in turn, greatly expands the repertoire of mechanisms used in modulating transcription without the need for expression of new regulatory molecules.
核受体是配体调节的转录因子,可将亲脂性配体的存在转化为基因表达的变化。核受体活性受配体诱导的与共激活因子或共抑制因子分子相互作用的调节。在没有激素的情况下,从正向激素反应元件(pHRE)来看,共抑制因子SMRT和N-CoR与一些核受体如甲状腺激素受体(T3Rs)和视黄酸受体结合,并介导对基础转录水平的抑制。配体结合导致共抑制因子解离和共激活因子结合,从而导致抑制作用的逆转和转录的净激活。然而,辅因子对来自负向HREs(nHREs)的核受体活性的作用了解甚少。在这里,我们表明共抑制因子SMRT可以作为来自nHRE的T3Rα的有效共激活因子;N-CoR具有类似但明显减弱的活性。T3Rα铰链区中阻止SMRT和N-CoR结合的残基的诱变抑制了来自nHRE的T3Rα的非配体依赖性转录激活。这些突变也消除了SMRT介导的T3Rα在nHRE处转录活性的增加,而不会显著影响在pHRE处的配体依赖性激活。部分蛋白酶消化与迁移率变动分析相结合表明,与pHRE相比,与nHRE结合的T3Rα-SMRT复合物的构象存在差异。这些结果表明,T3Rα与不同反应元件(即pHRE与nHRE)结合所导致的变构变化决定了辅因子将作为共激活因子还是共抑制因子发挥作用。反过来,这极大地扩展了用于调节转录的机制库,而无需表达新的调节分子。